Shots:
- It is based on P-lllb PONENTE trial assessing Fasenra (benralizumab, 30mg) in adult patients with severe Asthma on high-dose ICS + LABA and long-term use of OCS therapy with or without additional asthma controller. This study included approx. 600 patients in EU, North America, South America, and Taiwan
- Results: 62% of patients achieved complete elimination of daily OCS use on 1EP and on the 2EP, 81% of patients achieved complete elimination or were able to reduce their daily OCS dose to 5mg or less when further reduction was not possible due to adrenal insufficiency
- Fasenra is mAb that binds directly to IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of eosinophils via apoptosis. It is currently approved as an add-on maintenance treatment for severe eosinophilic asthma and is approved for self-administration in the US, EU and other countries
Click here to read full press release/ article | Ref: AstraZeneca | Image: Fox News
The post AstraZenca Reports Results of Fasenra (benralizumab) in P-lllb PONENTE Trial for Asthma first appeared on PharmaShots.
